Shanghai Fosun Pharmaceutical : ANNOUNCEMENT - ON COMPLETION OF THE ISSUANCE OF THE THIRD TRANCHE SUPER SHORT-TERM COMMERCIAL PAPERS FOR 2019

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT

ON COMPLETION OF THE ISSUANCE OF

THE THIRD TRANCHE SUPER SHORT-TERM

COMMERCIAL PAPERS FOR 2019

References are made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') dated 29 June 2017, 24 April 2018, 21 January 2019 and 30 July 2019 (the ''Announcements''), and the circular of the Company dated 11 May 2017, in relation to, among other things, the mandate to issue interbank market debt financing instruments. Unless otherwise specified, capitalized terms used herein shall have the same meaning as ascribed to them in the Announcements.

At the annual general meeting of the Company held on 29 June 2017, the resolution ''to consider and approve mandate to issue interbank market debt financing instruments'' was considered and approved, whereby the issuance of the inter-bank debt financing instruments, including but not limited to, super short-term commercial papers by the Company was approved. The Association has issued the SCP Notice on 17 April 2018, and the registration of the super short-term commercial papers was accepted, the registered amount of which is RMB5 billion. Such registered amount shall be effective for two years from the date of the issuance of SCP Notice (i.e. 17 April 2018). The Company may issue the super short-term commercial papers in tranches within the term of the registration.

The Company completed the issuance of the first tranche and the second tranche of super short-term commercial papers for 2019 in January 2019 and July 2019 in the aggregate principal amount of RMB1 billion and RMB0.3 billion, respectively.

- 1 -

The Company completed the issuance of the third tranche of super short-term commercial papers for 2019 (the ''Current Tranche of Super Short-term Commercial Papers'') recently. The results of the issuance of Current Tranche of Super Short-term Commercial Papers are set out below:

Name of the Current Tranche	The Third Tranche of Super Short-term Commercial Papers of
of Super Short-term	Shanghai Fosun Pharmaceutical (Group) Co., Ltd. for 2019* (上海
Commercial Papers	復星醫藥(集團)股份有限公司2019年度第三期超短期融資券)
Short Name of the Current	19 Fosun Pharma	Code of the	011902319
Tranche of Super Short-term	SCP003* (19復星醫	Current Tranche of
Commercial Papers	藥SCP003)	Super Short-term
		Commercial Papers
Aggregate principal amount	RMB0.5 billion	Term	60 days

Method of interest calculation Repayment of the principal and interest in lump sum at fixed rate on maturity

Nominal value per unit	RMB100	Coupon rate	2.90%
Value date	14 October 2019	Payment date	13 December 2019
Leading underwriter	China Merchants Bank Co., Ltd.
Joint leading underwriter	Bank of Ningbo Co., Ltd.

The relevant documents in relation to the Current Tranche of Super Short-term Commercial Papers have been published on the website of China Money at http://www.chinamoney.com.cn and the website of Shanghai Clearing House at http://www.shclearing.com.

- 2 -

This announcement does not constitute, or form part of, an offer or invitation, or solicitation or inducement of an offer, to subscribe for or purchase any of super short-term commercial papers or other securities of the Company, nor is this announcement circulated to invite offers for any securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

15 October 2019

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Wang Can, Ms. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

- 3 -